share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股SEC公告 ·  09/26 16:37

Moomoo AI 已提取核心訊息

Alterity Therapeutics, a development stage enterprise, has submitted its Corporate Governance Statement for the financial year ended June 30, 2024, as per the ASX Listing Rule 4.10.3. The statement, accurate as of September 26, 2024, outlines the company's adherence to the ASX Corporate Governance Council's Principles and Recommendations. It details the company's governance structure, including the roles and responsibilities of the Board and management, director appointments, performance reviews, and executive remuneration. The statement also addresses the company's commitment to ethical conduct, risk management, and the safeguarding of corporate reporting integrity. Alterity Therapeutics emphasizes the importance of diversity within its workforce, although it has not set specific measurable objectives for gender diversity due to the small size of its personnel. The company's Audit and Remuneration Committees are highlighted, along with their functions and the independence of their members. The statement further discusses the company's policies on communication, disclosure, shareholder rights, and remuneration, ensuring transparency and accountability in its operations.
Alterity Therapeutics, a development stage enterprise, has submitted its Corporate Governance Statement for the financial year ended June 30, 2024, as per the ASX Listing Rule 4.10.3. The statement, accurate as of September 26, 2024, outlines the company's adherence to the ASX Corporate Governance Council's Principles and Recommendations. It details the company's governance structure, including the roles and responsibilities of the Board and management, director appointments, performance reviews, and executive remuneration. The statement also addresses the company's commitment to ethical conduct, risk management, and the safeguarding of corporate reporting integrity. Alterity Therapeutics emphasizes the importance of diversity within its workforce, although it has not set specific measurable objectives for gender diversity due to the small size of its personnel. The company's Audit and Remuneration Committees are highlighted, along with their functions and the independence of their members. The statement further discusses the company's policies on communication, disclosure, shareholder rights, and remuneration, ensuring transparency and accountability in its operations.
alterity therapeutics，一家處於發展階段的企業，根據ASX上市規則4.10.3提交了截至2024年6月30日的公司治理報告。該報告截至2024年9月26日，詳細介紹了公司遵守ASX公司治理委員會原則和建議的情況。報告詳細說明了公司的治理結構，包括董事會和管理層的角色和職責、董事任命、績效評估和高管薪酬。報告還強調了公司對道德行爲、風險管理和維護公司報告誠信的承諾。alterity therapeutics強調了其員工多樣性的重要性，儘管由於其人員規模較小，尚未設定具體的性別多樣性可衡量目標。公司的審計委員會和薪酬委員會得到強調，介紹了它們的職能及成員的獨立性。報告進一步討論了公司的溝通、披露、股東權利和薪酬政策，確保其運營的透明度和問責制。
alterity therapeutics，一家處於發展階段的企業，根據ASX上市規則4.10.3提交了截至2024年6月30日的公司治理報告。該報告截至2024年9月26日，詳細介紹了公司遵守ASX公司治理委員會原則和建議的情況。報告詳細說明了公司的治理結構，包括董事會和管理層的角色和職責、董事任命、績效評估和高管薪酬。報告還強調了公司對道德行爲、風險管理和維護公司報告誠信的承諾。alterity therapeutics強調了其員工多樣性的重要性，儘管由於其人員規模較小，尚未設定具體的性別多樣性可衡量目標。公司的審計委員會和薪酬委員會得到強調，介紹了它們的職能及成員的獨立性。報告進一步討論了公司的溝通、披露、股東權利和薪酬政策，確保其運營的透明度和問責制。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間